№ files_lp_4_process_1_27866
File format: docx
Character count: 4849
File size: 26 KB
Official SEC filing detailing the acquisition and disposition of non-derivative and derivative securities by a company officer, including vesting schedules and beneficial ownership changes.
Year:
2026
Jurisdiction:
United States
Document Type:
SEC Filing
Regulatory Authority:
United States Securities and Exchange Commission
Form Type:
Form 4
Reporting Person:
Kreitzer Anatol
Position:
Chief Discovery Officer
Issuer:
MapLight Therapeutics, Inc. [MPLT]
Transaction Date:
02/05/2026
Securities Type:
Voting Common Stock, Employee Stock Options, Restricted Stock Units
Number of Shares Acquired:
6,020 (Common Stock), 24,455 (Options)
Vesting Schedule:
1/4 of RSUs on 01/01/2027, 1/16th on each subsequent April 1, July 1, October 1, and January 1; Options vest 1/4 on 02/05/2027, 1/48 each month thereafter
Filing Date:
02/09/2026
Attorney-in-Fact:
Kristopher L. Hanson
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
United States / Washington, D.C.
Subject:
Securities Sale Notification
Document Type:
Regulatory Filing
Agency:
Securities and Exchange Commission
Filer:
Robert Malenka
Issuer:
Maplight Therapeutics, Inc.
Filer Relationship to Issuer:
Director
Securities Type:
Common Stock
Number of Securities to Be Sold:
7039
Approximate Market Value:
126835.04 USD
Exchange:
NASDAQ
Acquisition Date:
January 23, 2026
Nature of Acquisition:
Restricted stock vesting under registered plan
Past Sales:
01/28/2026, 01/29/2026, 01/30/2026
Notice Date:
February 2, 2026
Signature:
/s/ Robert Malenka
Year:
2025
Region / City:
Singapore
Topic:
Target Validation, Drug Discovery
Document Type:
Call for Proposals
Organization:
Singapore Therapeutics Development Review (STDR)
Author:
N/A
Target Audience:
Researchers, Principal Investigators, Institutions
Period of Action:
2025
Approval Date:
N/A
Date of Last Changes:
N/A
Year:
2024
Region:
Africa
Document type:
Call for Expression of Interest (EOI)
Issuing organizations:
Africa CDC, Unitaid
Target audience:
Pharmaceutical manufacturers, CDMOs, CROs in Africa
Programmatic focus:
Maternal health, malaria, HIV, and related co-infections
Submission deadline:
August 15, 2024
Question deadline:
July 30, 2024
Issue date:
July 8, 2024
Supported interventions:
Safe Birth Africa project co-funded by European Union
Scope:
Regional manufacturing of therapeutics, diagnostics, and APIs
Product categories:
Oral solid dosage forms, sterile injectables, APIs
Year:
Not specified
Region / city:
Not specified
Theme:
Parkinson’s disease, therapeutic research
Document Type:
Pre-Clinical Proposal Template
Organization / Institution:
Michael J. Fox Foundation
Author:
Not specified
Period of validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Date:
April 22nd, 2025
Region / City:
Paris, France
Subject:
Immuno-oncology, Biotechnology
Document Type:
Press Release
Organization / Institution:
Egle Therapeutics
Author:
Egle Therapeutics
Target Audience:
Medical and scientific professionals in immuno-oncology and biotechnology
Period of Activity:
2025
Date of Approval:
April 22nd, 2025
Date of Changes:
N/A
Year:
Not specified
Region / city:
Not specified
Document Type:
Request for Applications
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers in Parkinson’s disease therapeutics
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2024
Region / city:
United States
Subject:
COVID-19 therapeutics development
Document type:
Request for Proposals (RFP)
Organ / institution:
Biomedical Advanced Research and Development Authority (BARDA)
Author:
Biomedical Advanced Research and Development Authority (BARDA)
Target audience:
Product developers, biomedical organizations
Period of validity:
2024–2027
Approval date:
05 August 2024
Amendment date:
20 August 2024
Note:
Year
Topic:
Neurology, Parkinson’s Disease
Document Type:
Request for Applications
Note:
Year
Subject:
Gene Transfer, Targeting, and Therapeutics
Document Type:
Request Form
Organization / Institution:
Salk Institute
Target Audience:
Researchers and Lab personnel
Context:
A form for requesting viral vectors from the Gene Transfer, Targeting, and Therapeutics Facility at the Salk Institute for scientific research purposes.
Year:
2026
Region / City:
La Jolla, CA
Topic:
Gene Transfer, Viral Vectors
Document Type:
Request Form
Organization / Institution:
Salk Institute for Biological Studies
Author:
GT3 Core Facility
Target Audience:
Researchers, Investigators
Validity Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2013
Region / city:
Gauteng Province
Theme:
Pharmaceuticals, Therapeutics, Rational Medicine Use
Document type:
Educational material
Institution:
Management Sciences for Health (MSH)
Author:
Management Sciences for Health
Target audience:
Healthcare practitioners, policy makers, and managers
Period of validity:
Indefinite
Approval date:
Not specified
Date of changes:
Not specified
Year:
2024
Region / city:
United States
Theme:
Gastrointestinal pharmacology, infectious diseases, antibiotic resistance, healthcare management
Document Type:
Review
Institution:
Hackensack Palisades Medical Center, Augusta University
Author:
Nagesh VK, Tran HHV, Elias D, Kianifar Aguilar I, Sethi T, Menon A, Mansour C, Furman F, Tsotsos K, Subar T, Auda A, Sidiqui A, Lamar J, Wadhwani N, Dey S, Lo A, Atoot A, Weissman S, Sifuentes H, Bangolo AI
Target Audience:
Healthcare professionals, researchers, medical practitioners
Period of Validity:
Ongoing studies, review is relevant until new treatments emerge
Date of Approval:
2024-07-25
Date of Changes:
2024-07-21
Facility:
Gene Transfer, Targeting and Therapeutics Facility
Institution:
Salk Institute for Biological Studies
Document Type:
Viral Vector Request Form
Subject:
Stock Reporter Viral Vectors
Submission Method:
Email to [email protected]
Required Information:
Principal Investigator, Lab Contact, Order Date, Fund Number or PO Number, Billing and Shipping Address
Aliquot Size AAV:
25 µl
Aliquot Size Lentiviral, Retroviral, Rabies:
5 µl
Vector Categories:
rAAV, Cre, DIO, FLEX, DO, Lentivirus, AAV Serotype Kits
Source References:
Addgene; Deisseroth Lab (Stanford University)
Material Transfer Requirement:
MTA required for Deisseroth Lab vectors
Titer Information:
Representative lot titers provided; actual titers may vary
Year:
2015
Region / City:
Southeastern/Southwest United States
Field:
Medicine, Oncology
Document Type:
Abstract
Organization:
Texas Tech University Health Sciences Center, University of Pennsylvania
Author:
Paul Trippier, Kshitij Verma, Tianzhu Zang, Trevor M. Penning
Target Audience:
Researchers, Medical Professionals
Effective Period:
Not specified
Approval Date:
Not specified
Date of Last Update:
Not specified